Shopping Cart 0
Cart Subtotal
USD 0

Quantum Genomics SA (ALQGC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Quantum Genomics SA (Quantum Genomics) is a biopharmaceutical company which develops novel medicines in the field of cardiovascular diseases. The company develops drugs to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform. Quantum Genomics BAPAI products pipeline include QGC001 for the treatment of high blood pressure with monotherapy drug; and QGC011 for the treatment of hypertension through combination therapy in pre-clinical phase. The company offers QGC006 for the optimization of the treatment of hypertension with a monotherapy drug; and QGC101 for the prevention and treatment of heart failure. The company partners with biotech research entities, academic teams, and pharmaceutical and bio-science companies to develop new drugs. QGS is headquartered in Paris, France.

Quantum Genomics SA (ALQGC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11

Quantum Genomics Enters into Co-Development Agreement for QGC101 12

Equity Offering 13

Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13

Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14

Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15

Quantum Genomics Raises USD6 Million in Private Placement of Shares 16

Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17

Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19

Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20

Debt Offering 21

Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21

Quantum Genomics SA-Key Competitors 22

Quantum Genomics SA-Key Employees 23

Quantum Genomics SA-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Strategy And Business Planning 25

Apr 19, 2018: Quantum Genomics enters a new phase of maturity with its BAPAIs Fast Growth strategic plan 25

Financial Announcements 28

Mar 29, 2018: Quantum Genomics publishes its financial results for the year 2017 28

Oct 03, 2017: Quantum Genomics Releases 2017 First-Half Financial Results and First Nine Months Business Update 30

Mar 30, 2017: Quantum Genomics: 2016 annual financial results 32

Corporate Communications 34

Apr 09, 2018: Quantum Genomics strengthens its governance 34

Feb 05, 2018: Quantum Genomics strengthens its Scientific Advisory Board with the appointment of Professor Frans Leenen, a renowned expert in congestive heart failure 35

Jul 11, 2017: Quantum Genomics begins trading in the U.S. on OTCQX 36

Jun 30, 2017: Quantum Genomics appoints Professor Toshiro Fujita as member of its Scientific Advisory Board 37

Apr 25, 2017: Quantum Genomics appoints Bruno Besse as Chief Medical Officer 38

Product News 39

10/27/2017: Quantum Genomics receives the Galien MedStartUp award for the innovative design of its NEW-HOPE study 39

10/16/2017: Quantum Genomics nominated for the Galien MedStartUp Award for the innovative design of its NEW-HOPE trial 40

06/04/2018: FIRIBASTAT Approved as Common International Name for QGC001 by World Health Organization 41

Clinical Trials 42

Nov 15, 2017: Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States 42

Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001 43

Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE 44

Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension 46

May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure 48

Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Quantum Genomics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Quantum Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Quantum Genomics SA, Deals By Therapy Area, 2012 to YTD 2018 9

Quantum Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Quantum Genomics Enters into Research Agreement with University of Ottawa Heart Institute and Center for Interdisciplinary Research in Biology 11

Quantum Genomics Enters into Co-Development Agreement for QGC101 12

Quantum Genomics to Raise USD7.4 Million in First Tranche of Private Placement of Shares 13

Quantum Genomics Raises USD9.6 Million in Private Placement of Shares 14

Quantum Genomics Raises USD3.4 Million in Public Offering of Shares 15

Quantum Genomics Raises USD6 Million in Private Placement of Shares 16

Quantum Genomics Completes Underwriters Exercise of Over-Allotment Option of IPO for USD14.4 Million 17

Quantum Genomics Raises Additional USD0.33 Million in Private Placement of Shares 19

Quantum Genomics Raises USD4.7 Million in Private Placement of Shares 20

Quantum Genomics Raises USD3.7 Million in Public Offering of Bonds 21

Quantum Genomics SA, Key Competitors 22

Quantum Genomics SA, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Quantum Genomics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.